Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

New data shows safety and efficacy of biosimilar infliximab treatment in IBD patients

Clinical experience of biosimilar infliximab in 78 inflammatory bowel disease (IBD) patients presented at Digestive Diseases Week (DDW) 2015 in Washington D.C. showed that the treatment is comparable to the reference medicinal product (RMP) in terms of efficacy and safety.

20 May 2015

Immune Pharmaceuticals announces Q1 2015 financial results; files Quarterly Report on Form 10-Q

Immune Pharmaceuticals Inc. announced financial results for the first quarter ended March 31, 2015. Immune filed its Quarterly Report on Form 10-Q for the first quarter of 2015 on Friday, May 15, 2015.

18 May 2015

Results from four major studies on cancer treatments to be presented at ASCO Annual Meeting

The American Society of Clinical Oncology today announced results from four major studies to be presented at ASCO's 51st Annual Meeting, May 29-June 2, in Chicago. Findings showed that use of a widely available vitamin pill reduces the risk of non-melanoma skin cancers; that early chemotherapy extends the lives of men with advanced prostate cancers; and that new therapies can improve outcomes for children with a rare form of kidney cancer and adults with relapsed multiple myeloma.

15 May 2015

TSRI researchers find interferon beta protein as prime suspect in persistent viral infections

Interferon proteins are normally considered virus-fighters, but scientists at The Scripps Research Institute have found evidence that one of them, interferon beta (IFNβ), has an immune-suppressing effect that can help some viruses establish persistent infections.

14 May 2015

Study: Disrupting cancer pathway could extend benefits of new immunity-boosting drugs

Understanding how to overrule a signaling pathway that can cause treatments to fail in metastatic melanoma patients should help physicians extend the benefits of recently approved immunity-boosting drugs known as checkpoint inhibitors to more patients.

12 May 2015

Raising lupus awareness: an interview with Professor Ramsey-Goldman, MD

Lupus is a chronic, autoimmune disease, with many different symptoms so it is hard to diagnose. It affects each person differently and it has an unpredictable disease course with flare ups and quiet time. Some patients describe lupus as if they are riding a roller coaster with blinders on because they cannot always tell when they will feel well or sick...

11 May 2015

Stanford University professor named recipient of 2015 ECOG-ACRIN Young Investigator Award

Heather Wakelee, MD, is the recipient of the 2015 ECOG-ACRIN Young Investigator Award, the ECOG-ACRIN Cancer Research Group announced today. Dr. Wakelee is associate professor of medicine in the Division of Oncology at the Stanford University School of Medicine in Stanford, Calif.

7 May 2015

Preclinical data from Synthetic Biologics' SYN-005 for Pertussis treatment presented at ECCMID 2015

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced that preclinical data from its novel SYN-005 program for the treatment of Pertussis were presented in two posters at ECCMID 2015 (European Congress of Clinical Microbiology and Infectious Diseases), on April 25, 2015, in Copenhagen, Denmark.

27 Apr 2015

Astellas, Potenza collaborate to develop immuno-oncology therapeutics for patients with certain cancers

Astellas Pharma Inc. and Potenza Therapeutics, Inc., a biotechnology company developing a portfolio of immuno-oncology programs, today announced an exclusive research and development collaboration.

22 Apr 2015

Study: Extending natalizumab treatment effective in preventing MS symptoms

In a study of 1,964 patients with multiple sclerosis (MS) led by researchers at the NYU Langone Multiple Sclerosis Comprehensive Care Center, extending the dose of natalizumab from 4 weeks up to 8 weeks was shown to be well-tolerated and effective in patients, and resulted in no cases of the potentially fatal side effect progressive multifocal leukoencephalopathy (PML).

21 Apr 2015

New drug combination shows promise in patients with metastatic melanoma

Once again, researchers at Penn's Abramson Cancer Center have extended the reach of the immune system in the fight against metastatic melanoma, this time by combining the checkpoint inhibitor tremelimumab with an anti-CD40 monoclonal antibody drug.

20 Apr 2015

Researchers explore benefits and risks of biosimilar antibodies

In the emerging biosimilar market, biosimilar antibodies are being developed to treat conditions currently addressed by their original, targeted biological therapy. Only a few biosimilars are approved by the EMA, and just one has been approved by the FDA. In a review article, researchers used the clinical development data from one drug to explore the broader benefits and risks of these cost-effective, but as yet unfamiliar treatment options.

17 Apr 2015

Effimune obtains regulatory approval for Phase I clinical trial in humans of its new immunomodulator FR104

Effimune announced today that it had received the authorization from the Belgian regulatory authority, the FAMHP (Federal Agency for Medicines and Health Products) for a Phase I clinical trial of FR104, its drug candidate for controlling the regulation of the immune system...

16 Apr 2015

NIST researchers develop new 2D NMR fingerprinting method to measure monoclonal antibodies

National Institute of Standards and Technology researchers at the Institute for Bioscience and Biotechnology Research have demonstrated the most precise method yet to measure the structural configuration of monoclonal antibodies (mAbs), an important factor in determining the safety and efficacy of these biomolecules as medicines.

16 Apr 2015

New longer-term data on Genzyme's relapsing MS treatments to be presented at AAN 2015

Genzyme, a Sanofi company, announced today that new longer-term data on its relapsing multiple sclerosis treatments, Aubagio (teriflunomide) and Lemtrada (alemtuzumab), will be featured during the 67th annual meeting of the American Academy of Neurology being held in Washington, D.C. April 18-25.

15 Apr 2015

Vanderbilt researchers join multi-center effort to accelerate development of potential Ebola therapy

Vanderbilt University researchers have joined a multi-center effort led by Pennsylvania-based Inovio Pharmaceuticals Inc. to accelerate development of potential antibody therapies against the often-lethal Ebola virus.

9 Apr 2015

MabVax closes $11.6 million in private placement

MabVax Therapeutics Holdings, Inc., a clinical-stage cancer immunotherapy company, is pleased to announce that it has closed on gross proceeds of approximately $11.6 million in a private placement (the "Private Placement") led by OPKO Health, Inc. and Dr. Phillip Frost, CEO and Chairman of OPKO Health.

6 Apr 2015

Astellas Pharma, MD Anderson sign option agreement to research and develop new treatment for AML

Astellas Pharma Inc. and The University of Texas MD Anderson Cancer Center today announced the signing of an option agreement to research and develop a new treatment for patients with acute myeloid leukemia (AML).

6 Apr 2015

World-first human clinical trials for Hendra virus to begin this month

An antibody manufactured at The University of Queensland will be used in world-first human Hendra virus clinical trials starting this month.

1 Apr 2015

Study provides insights into basis for cognitive dysfunction

Scientists at Columbia University's Mailman School of Public Health have identified a unique pattern of immune molecules in the cerebrospinal fluid of people with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) that provides insights into the basis for cognitive dysfunction--frequently described by patients as "brain fog"--as well as new hope for improvements in diagnosis and treatment.

31 Mar 2015

Monoclonal Antibody News and Research

Further Reading

New data shows safety and efficacy of biosimilar infliximab treatment in IBD patients

Immune Pharmaceuticals announces Q1 2015 financial results; files Quarterly Report on Form 10-Q

Results from four major studies on cancer treatments to be presented at ASCO Annual Meeting

TSRI researchers find interferon beta protein as prime suspect in persistent viral infections

Study: Disrupting cancer pathway could extend benefits of new immunity-boosting drugs

Raising lupus awareness: an interview with Professor Ramsey-Goldman, MD

Stanford University professor named recipient of 2015 ECOG-ACRIN Young Investigator Award

Preclinical data from Synthetic Biologics' SYN-005 for Pertussis treatment presented at ECCMID 2015

Astellas, Potenza collaborate to develop immuno-oncology therapeutics for patients with certain cancers

Study: Extending natalizumab treatment effective in preventing MS symptoms

New drug combination shows promise in patients with metastatic melanoma

Researchers explore benefits and risks of biosimilar antibodies

Effimune obtains regulatory approval for Phase I clinical trial in humans of its new immunomodulator FR104

NIST researchers develop new 2D NMR fingerprinting method to measure monoclonal antibodies

New longer-term data on Genzyme's relapsing MS treatments to be presented at AAN 2015

Vanderbilt researchers join multi-center effort to accelerate development of potential Ebola therapy

MabVax closes $11.6 million in private placement

Astellas Pharma, MD Anderson sign option agreement to research and develop new treatment for AML

World-first human clinical trials for Hendra virus to begin this month

Study provides insights into basis for cognitive dysfunction

Immunology eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®